<?xml version="1.0" encoding="UTF-8"?>
<p id="p0310">Interest in peptide vaccines has grown over the years, especially with indications of good results against viruses that cause cancers. The number of peptide vaccines listed in 
 <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="ir0045" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> website of the NIH, United States lists at present 591 projects under various phases of field trials. Of these, 466 relate to anticancer peptide vaccine trials, 92 are peptide vaccines against HIV, 16 are for influenza viruses, the trials being conducted by institutions, academia, and commercial firms. The majority are at the Phase I and Phase II trials, but 16 projects are listed in Phase III, including a few on enterovirus and Alzheimerâ€™s disease but with the majority related to various cancers.
</p>
